The Experimental Research Of Somatostatin And Its Analogue On Pancreatic Cancer Cell Proliferation、Apoptosis And VEGF Expression

Objective:Pancreatic cancer is a common pancreatic malignant neoplasm, whose early diagnosis is difficult and surgical resection rate is low. It is not sensitive enough to chemotherapy and radiotherapy. Up to now, there is no ideal treatment method. Malignant tumor’s invasion and metastasis depend on tumor angiogenesis, and vascular endothelial growth factor(VEGF) play a major role. Somatostatin and its analogue have a role of inhibition in solid tumor. This study was designed to explore the effects of somatostatin and its analogue on pancreatic cancer cell proliferation, apoptosis and expression of VEGF.Methods:The pancreatic cancer cell SW1990was cultured in the incubator. The cells were shoped into96-well cell culture plate after cell count. The cells were effected with different concentrations of14peptide somatostatin(Stilamin) and its analogue8peptide(Octreotide)(0ng/ml、50ng/ml、200ng/ml、400ng/ml、800ng/ml、1600ng/ml) for24h、48h and72h, and then the OD value were assayed by MTT method. The rate of cell proliferation was calculated according to the OD value. The cells were shoped into6-well cell culture plate within a slides, and were effected with Stilamin and Octreotide(800ng/ml). After24h, the cell apoptosis was assayed by TUNEL method. The cells were effected with different concentrations of Stilamin and Octreotide (Ong/ml、50ng/ml、200ng/ml、400ng/ml、800ng/ml、1600ng/ml). After24h, the expression of VEGF-mRNA was assayed the by RT-PCR method.Results:Different concentrations of somatostatin inhibited pancreatic cancer cell proliferation, and with the increasing drug concentration, pancreatic cancer cell proliferation rate decreased significantly(P<0.05). But the inhibition of cell proliferation rate decreased with the time of drug action(P<0.05). Both Stilamin and Octreotide could promote apoptosis of pancreatic cancer cell. There were significant differencesbetween the groups(P<0.05). Different concentrations of somatostatin could reduce the expression of pancreatic cancer cell VEGF-mRNA, and with the drug concentration increased, the expression of pancreatic cancer cell VEGF-mRNA decreased significantly (P<0.05).Conclusion:Somatostatin and its analogue can inhibit pancreatic cancer cell proliferation which depend on drug concentration. But with the time of drug action, the cell proliferation gradually increased. The inhibition of cell proliferation of Somatostatin and its analogue decreased. Both Stalimin and Octreotide can promote the apoptosis and reduce the VEGF-mRNA expression. With the drug concentration increased, the VEGF-mRNA expression decreased significantly. Our study provides experimental basis for somatostatin and its analogue clinically used in the treatment of pancreatic cancer.